The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma (Q33737175)

29 July 2017

title

The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma (English)

1 reference

29 July 2017

0 references

Dave Singh

1

1 reference

29 July 2017

Frank Petavy

2

1 reference

29 July 2017

Alex J Macdonald

3

1 reference

29 July 2017

Aili L Lazaar

4

1 reference

29 July 2017

Brian J O'Connor

5

1 reference

29 July 2017

publication date

1 March 2010

1 reference

29 July 2017

1 reference

29 July 2017

volume

11

1 reference

29 July 2017

page(s)

26

1 reference

https://scigraph.springernature.com/pub.10.1186/1465-9921-11-26

29 July 2017

exact match

0 references

cites work

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841147

PDE4 inhibitors: current status

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841147

Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841147

Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841147

Are phosphodiesterase 4 inhibitors just more theophylline?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841147

Glucocorticoids: effects on gene transcription

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841147

Use of exhaled nitric oxide measurements to guide treatment in chronic asthma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841147

Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841147

In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841147

Therapeutic potential of selective PDE inhibitors in asthma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841147

Phosphodiesterase isozymes: molecular targets for novel antiasthma agents

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841147

The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841147

Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841147

Theophylline toxicity: clinical features of 116 consecutive cases

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841147

Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-11-26

Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-11-26

The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-11-26

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-11-26

Differential effects of fluticasone and montelukast on allergen-induced asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-11-26

Effect of low-dose ciclesonide on allergen-induced responses in subjects with mild allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-11-26

Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-11-26

A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-11-26

Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841147

Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease

30 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-11-26

Selective Inducible Nitric Oxide Synthase Inhibition Has No Effect on Allergen Challenge in Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-11-26

T cells and cytokines in bronchoalveolar lavage fluid after segmental allergen provocation in atopic asthma

21 January 2018

1 reference

12 December 2020

Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor

1 reference

12 December 2020

The effects of inhaled budesonide and formoterol in combination and alone when given directly after allergen challenge

1 reference

12 December 2020

Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies

1 reference

12 December 2020

Identifiers

DOI

10.1186/1465-9921-11-26

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference

29 July 2017

1 reference